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The recent development of interferon-free regimens based on direct-acting antivirals for
the  treatment of chronic hepatitis C virus infection has beneﬁted many but not all patients.
Some patients still experience treatment failure, possibly attributed to unknown host and
viral  factors, such as IFNL3 gene polymorphism. The present study assessed the preva-
lence of rs12979860-CC, rs12979860-CT, and rs12979860-TT genotypes of the IFNL3 gene,
and its relationship with ancestry informative markers in 949 adult Brazilian healthy blood
donors. Race was analyzed using ancestry informative markers as a surrogate for ances-
try.  IFNL3 gene was genotyped using the ABI TaqMan single nucleotide polymorphisms
genotyping assays. The overall frequency of rs12979860-CC genotype was 36.9%. The contri-
bution of African ancestry was signiﬁcantly higher among donors from the northeast region
in  relation to southeast donors, whereas the inﬂuence of European ancestry was signiﬁ-
cantly higher in southeast donors. Donors with rs12979860-CC and rs12979860-CT genotypes
had similar ancestry background. The contribution of African ancestry was higher among
rs12979860-TT genotype donors in comparison to both rs12979860-CC and rs12979860-
CT  genotypes. The prevalence of rs12979860-CC genotype is similar to that found in the
US, despite the Brazilian ancestry informative markers admixture. However, in terms of
ancestry, rs12979860-CT genotype was much closer to rs12979860-CC individuals than tors12979860-TT.
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Introduction
Chronic hepatitis C (CHC) virus infection is a global disease
that imposes a major global health burden. In a recently
published study, the world prevalence of anti-HCV was esti-
mated at 1.6% (1.3–2.1%), corresponding to 115 (92–149) million
infections.1
Evidence suggests that the ability to control viral repli-
cation is related to viral and host factors. Several studies
have demonstrated that a strong initial innate and adaptive
immune response against hepatitis C virus (HCV) favors viral
clearance.2–4 Thus, variation in genes involved in the immune
response may contribute to the ability to clear the virus.2
In 2009, single nucleotide polymorphisms (SNP) of the
IFNL3 gene (rs12979860) were related to natural clearance of
HCV.3,5 According to this genome-wide study, rs12979860-CC
genotype was associated with spontaneous HCV infection
resolution among individuals of both European and African
ancestry. Further investigations have implicated IFNL3 gene
polymorphisms in the development of spontaneous resolu-
tion of acute infection and therapeutic cure of HCV-infected
patients treated with interferon-based regimens.6
Before 2011, interferon-based therapy was the standard-
of-care for treating HCV. Recently, interferon-free regimens
based on direct-acting antivirals (DAAs) have revolutionized
the treatment of CHC. Compared to conventional interferon-
based regimens, DAAs have demonstrated greater sustained
virological response (SVR) rates, shorter treatment duration,
increased tolerability, and lower incidence of adverse events.7
Nonetheless, some patients still experience treatment failure
due to on-treatment viral breakthrough or relapse after cessa-
tion of therapy, possibly attributed to unknown host and viral
factors, such as IFNL3 gene polymorphism.
Toward that end, data from a recently published subgroup
analysis of only eight weeks of ledipasvir plus sofosbuvir
for genotype 1 HCV showed SVR rates varying signiﬁcantly
according to rs12979860 genotype. In rs12979860-CC genotype
patients SVR rate were in excess of 98%, whereas SVR rates
were 95.1% and 90.9%, in rs12979860-CT and TT genotype,
respectively (p = 0.02). Those results prompted discussion on
the relationship of polymorphisms near the IFNL3 gene and
SVR to DAA-based regimens.8
Patients of European ancestry have a signiﬁcantly higher
probability of being cured with interferon-based regi-
mens than patients of African ancestry. The frequency of
rs12979860-CC genotype is substantially greater in European
than in African populations. This genetic polymorphism also
explains approximately half of the difference in response
rates between African-Americans and patients of European
ancestry.5
Brazilians are one of the most heterogeneous popula-
tions in the world, resulting of ﬁve centuries of interethnic
crosses between European, Africans, and autochthonous
Amerindians.9 A growing number of publications have
reported the use of ancestry-informative markers (AIMs)
whose allele frequency varies signiﬁcantly between popu-
lations of distinct geographic origins in order to estimate
individual admixture and to identify population substructure.
In most studies, these AIMs consisted of single-nucleotide 1 6;2  0(6):619–622
polymorphisms (SNPs), but insertion-deletion polymorphisms
(INDELs) of small DNA fragments and short tandem repeats
have also been used.10–13
Thus, the objectives of the present study were to assess the
prevalence of rs12979860-CC, rs12979860-CT, and rs12979860-
TT genotypes of the IFNL3 gene and its relationship with
ancestry markers in a Brazilian population.
Between January 2nd and July 31st 2011, 949 healthy adult
blood donors were selected from the Colsan blood bank net-
work, in São Paulo, Brazil. Of those, 420 were originally from
the northeast region and 529 from the southeast region. This
study was approved by Research Ethics Committee of the Fed-
eral University of São Paulo (UNIFESP).
Samples of peripheral blood from each subject were col-
lected in 0.5 M EDTA tubes, and genomic DNA was extracted
from mononuclear cells using DNA blood Mini kit (QIAamp,
Qiagen, Inc., Valencia, CA, USA) according to the manufac-
turer’s instructions.
The rs12979860 was genotyped using the ABI Taq-
Man SNP genotyping assays (Applied Biosystems, Foster
City, CA, USA). Primers that contemplated polymorphism
were IL28B Foward: 5′ GCCTGTCGTGTACTGAACCA 3′ and
IL28B Reverse: 5′ GCGCGGAGTGCAATTCAAC 3′ (Euroﬁns MWG
Operon, Hunstsville, AL, USA), TaqMan® MGB  Probes (Applied
Biosystems, Foster City, CA, USA) for each allele which were
labeled with a different ﬂuorophore: 5′ TGGTTCGCGC CTTC 3′
– VIC and 5′ CTGGTTCA CGCCTTC 3′ – FAM.5 The total reac-
tion volume was 8.5 L containing: 1.1 L H2O; genotyping 5 L
TaqMan Master Mix (Applied Biosystems, Foster City, CA); 5 pM
primers; 25 pM probe (Applied Biosystems, Foster City, CA) and
cycled in PCR machine Real® time 7500 (Applied Biosystems,
Foster City, CA, USA) according to standard cycling as follows:
denaturation at 95 ◦C for 10 min, followed by 40 cycles of dena-
turation at 92 ◦C for 15 s, annealing and extension at 60 ◦C for
1 min. The results were analyzed by using Software System
7500 (Applied Biosystems, Foster City, CA).
Genetic ancestry was determined by analyzing AIMs. DNA
samples were typed for 48 biallelic INDELs using three 16-plex
PCR reactions as previously described.10 DNA fragments were
separated using an ABI PRISM 3130 Genetic Analyzer (Applied
Biosystems) and analyzed with GeneMapper ID v3.2 software
(Applied Biosystems).10
Also, at the time of blood donation participants were
asked to inform their perceived race, as Caucasian or African-
descendent.
Results  and  discussion
Our study evaluated the link between race and polymorphisms
near the IFNL3 (formerly known as IL28B) gene among healthy
voluntary blood donors using AIM as a surrogate for ances-
try. A total of 949 blood donors were included, 420 (44.25%)
from the northeast region and 529 (55.75%) from the south-
east region; 328 (34.6%) females and 621 (65.4%) males. The
overall frequency of rs12979860-CC genotype was 36.9%, with
a tendency for greater prevalence among donors born in
the southeast (39.3%) than in the northeast (33.8%; p = 0.08)
regions. The average AIM of African ancestry was signiﬁcantly
higher among donors from the northeast region (0.279) in
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elation to the southeast (0.225; p < 0.001), whereas the average
IM of European ancestry was signiﬁcantly higher in south-
ast donors. The ancestry background was similar between
s12979860-CC genotype and rs12979860-CT genotype donors.
frican ancestry was higher among rs12979860-TT genotype
onors in comparison to both rs12979860-CC genotype and
s12979860-CTdonors.
In the present study, the prevalence of rs12979860-CC,
s12979860-CT, and rs12979860-TT genotypes were 36.9%,
9.1% and 14%, respectively. The rs12979860-CC genotype in
outheastern donors (39.3%) tended to be more  frequent than
mong northeastern donors (33.8%; p = 0.08). On the contrary,
s12979860-TT genotype was more  prevalent in northeastern
onors (17.4%) than in southeastern donors (11.3%; p = 0.01).
 previous Brazilian study conducted in the northeast city
f Salvador, Bahia, evaluated 222 HCV infected patients and
ound that the prevalence of rs12979860-CC (24.4%) was lower,
f rs12979860-TT (20.8%) higher, and of rs12979860-CT (54.7%)
as similar to our study ﬁndings. The encountered discrep-
ncy of rs12979860-CC and rs12979860-TT prevalence in the
wo studies could be due to higher representation of blacks
n the Salvador study. Indeed, the self-reported prevalence
f African-descendants in our study (11.4%) was much lower
han that of the Salvador study (36.8%).9
A study in 88 Japanese HCV infected patients showed
 prevalence of 64.3% of rs12979860-CC and 38.7% of
s12979860-CT genotypes. No rs12979860-TT genotype was
ncountered.14 In China, three large studies with hepatitis B
nfected patients found rates of rs12979860-CC genotype over
5% and rs12979860-TT genotype around 5%.14–17
In the United States, where miscegenation remains very
ow, the prevalence of rs12979860-TT genotype among HCV
nfected self-reported African descendants is signiﬁcantly
reater than that found in self-reported Caucasians, 37%
nd 12%, respectively.18 Interestingly the prevalence of
s12979860-CT genotype in Caucasians (49%) was similar to
hat of African descendants (51%).
Two studies conducted in Spain evaluated 283 and 119 HCV-
nfected patients. The rates of rs12979860-CC genotype were
4.7% and 41.1%, respectively.19,20 These rates are similar to
hose found in Germany (40.2%),21 but lower to the prevalence
ound in Egypt (54%), an intermediary value between rates
ound among Asians and Caucasians.22
Our results show that Brazilian adult healthy blood donors
ave a prevalence (36.7%) of rs12979860-CC genotype similar
o that found in the US, despite its heterogeneous popu-
ation mix. The prevalence of rs12979860-CT genotype was
lso similar to that of other western countries. However, in
erms of ancestry, rs12979860-CT genotype was much closer
o rs12979860-CC individuals than to rs12979860-TT. Accord-
ngly, one could question whether the likelihood of viral
learance among rs12979860-CT Brazilian individuals is closer
o that observed in rs12979860-CC than in rs12979860-TT indi-
iduals. The same would also apply for the HCV treatment
esponse.
The overall frequency of rs12979860-TT genotype observed
n our study was 14.0%, nearly the same as other west-
rn countries. In these cases, treatment failure due to
n-treatment viral breakthrough or relapse after cessation
f therapy may be attributed to an ineffective endogenous
16;2 0(6):619–622 621
interferon response unable to promote viral clearance and,
hence, raise the emergence of RAVs.
Despite the large sample size, our study results may not
necessarily be representative for the entire Brazilian popula-
tion.
Finally, the role of CT genotype in viral clearance and treat-
ment response should be further evaluated in populations
with signiﬁcant and prolonged interethnic crosses such as the
Brazilian population.
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